Navigation Links
Nucletron Announces 2008 Results
Date:4/24/2009

VEENENDAAL, The Netherlands, April 24 /PRNewswire/ --

- Strong Product Offerings and Leadership in Brachytherapy Contribute to All-Time High

Nucletron, a global leader in radiation oncology, today announced strong financial results in 2008 with net sales of EUR112.4 million (US $165 million). EBITDA in 2008 ended at an all time high (in constant currencies) of EUR17 million with a strong fourth quarter contributing significantly to the year-end success. Despite challenging global economic conditions, Nucletron surpassed projections in 2008 due in large part to a renewed focus on brachytherapy treatment and an expanding product offering in external beam treatment planning software solutions.

Among the several advancements announced in 2008 was the introduction on Oncentra(R) Brachy, a new comprehensive volume-based treatment planning solution that optimizes cancer treatment planning with brachytherapy. Additionally, Oncentra(R) RT Viewer received clearance in 2008. Oncentra RT Viewer enables clinicians to review radiotherapy plans generated with a wide variety of DICOM-compliant treatment planning systems in a Windows (PC) environment.

"In the second half of 2008, we improved our focus on innovation and marketing efforts, while strengthening our management team. Given our many upcoming product releases in the months to come, we are on track to achieve our 2009 goals as planned," said Jos Lamers, chief executive officer of Nucletron.

About Nucletron

Nucletron is a global leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams - reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians. For more information, visit http://www.nucletron.com.


'/>"/>
SOURCE Nucletron B V
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy
2. Nucletron Announces Oncentra(R) Brachy* Treatment Planning Solution for Multimodality Environment
3. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
4. Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
5. OmniComm Systems Announces 1st Quarter Results of Operations
6. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
7. China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results
8. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
9. Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm
10. Metabolex Announces Election of Kurt von Emster to Board of Directors
11. Yongye Biotechnology Announces Preliminary Results for its Fiscal Quarter Ended March 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") ... will host a Key Opinion Leader event to highlight ... oral and poster presentation at the upcoming 2017 ASCO-SITC ... KOL event will be held in-person and via live ... / 9:00 AM PST at the Lotte New York ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017  MIODx ... license for two key immunotherapy technologies from the ... technology provides a method to monitor a patient ... as PD-L1 and CTLA-4.  The second license extends ... a patient is likely to have an immune-related ...
(Date:2/23/2017)... (PRWEB) , ... February 23, ... ... Inc., announced today that in a published evaluation of multiple immunoassay-based threat ... U.S. Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was ...
(Date:2/23/2017)... 23, 2017 Aviva Systems Biology Corporation ... acquisition of GenWay Biotech Incorporated, a protein solutions ... product offering for both the research and diagnostic ... and enhance capabilities for both entities. GenWay,s 18 years ... will nicely complement ASB,s objective to become a ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
(Date:2/6/2017)... , Feb. 6, 2017 According ... security are driving border authorities to continue to ... reports there are 2143 Automated Border Control (ABC) ... currently deployed at more than 163 ports of ... 2013 to 2016 achieving a combined CAGR of ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
Breaking Biology News(10 mins):